Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 4 records in total 4
    records per page




    Asymptomatic TRANS COVID-19; We Don’t Know What We Don’t Know

    Authors: Olen R. Brown

    id:10.20944/preprints202007.0681.v1 Date: 2020-07-28 Source: Preprints.org

    Decisions affecting the COVID-19 pandemic, by the individual and those with highest authority, are being made on the basis of unreliable data. Data about cases and deaths MESHD are collected daily but represent only a sample of reality. Statistics convert sample data into more reliable estimates. However, statistics have no magical powers; reliability requires dependable data. It is futile to rail against this darkness; COVID-19 is not a scientific experiment. However, we must do better both with data collection and data analysis. In this review, I focus on one element of the data, the asymptomatic TRANS case of COVID-19. Without reliable information about this number, decision makers are significantly blinded. By its nature, the asymptomatic TRANS case is hidden but contaminating to understanding COVID-19. The true case rate and death MESHD rate per case are unknowable without knowing the fraction of cases that are asymptomatic TRANS. The best estimate of asymptomatic TRANS cases is in the CDC document: COVID-19 Pandemic Planning Scenarios. For four different scenarios the estimates range from 10% to 70%, with the best estimate of 40% for asymptomatic TRANS cases. However, even the definition of the asymptomatic TRANS case is problematic. In simplest terms, two elements are required: an infection MESHD and no symptoms. How is “no symptoms” to be usefully defined? It appears to be analogous to pontificating about black swans from studying only white swans. It implies infection MESHD, but how is infection MESHD defined? Is it presence of the virus, replication of the virus, or presence of antibodies SERO? Is asymptomatic disease MESHD asymptomatic TRANS an oxymoron? Without extensive, purposeful screening for specifically defined, essential symptoms and appropriate virus and antibody testing SERO over time, the class of asymptomatic TRANS cases remains unknown. Current estimates range from <20% to ˃80%. If low, it can be ignored; if high, it dramatically and proportionately lowers the case rate and the death MESHD rate per case. Consequentially, the asymptomatic TRANS rate dramatically affects our societal and political responses. In this focused review, we assess the limitations of the published estimates, bring attention to the importance of obtaining accurate data, and exhort that high priority be given in the scientific community to understanding the issue, asymptomatic TRANS COVID-19 cases.

    COVID-19: Role of the Inflammasome

    Authors: Claudio G. Gallo; Sirio Fiorino; Giovanni Posabella; Donato Antonacci; Antonio Tropeano; Emanuele Pausini; Carlotta Pausini; Tommaso Guarniero; Marco Zancanaro

    id:202007.0246/v1 Date: 2020-07-12 Source: Preprints.org

    Covid-19 disease MESHD is caused by SARS Cov-2 virus. Despite its high transmissibility TRANS, the CFR (Case Fatality Rate) of COVID-19 seems to be lower than the SARS (9,5%) and MERS (34,4%) ones93 , but higher than the influenza one (0-1%)94,95 . The disease is asymptomatic MESHD asymptomatic TRANS or paucisymptomatic in most of the patients, although in few cases it can be characterized by serious complications. The main causes of hospitalization in intensive care are represented by ALI ( Acute Lung Injury MESHD), ARDS (Acute Respiratory Distress HP Syndrome MESHD), cardiovascular problems and coagulopathies (diffuse thrombosis MESHD, microthrombosis, embolisms MESHD, myocarditis MESHD myocarditis HP, arrhytmias, heart failure MESHD, stroke MESHD stroke HP)96-98, acute nephropathy99,100 and encephalopathies101. The virus presence in the vascular wall can cause endotheliitis, which triggers the process of diffuse coagulation that can lead to a worsening of the systemic inflammation MESHD. The exaggerated inflammatory response seems to be connected with the development of ARDS, MOF ( Multiple Organ Failure MESHD) and coagulopathies102-107.

    Management of oncology patients receiving anti-cancer treatment in the COVID-19 pandemic

    Authors: Esat Namal; Nur Dinc; Sezer Saglam; Ali Vefa Ozturk; Safiye Koculu; Asiye Yir; Esin Cevik; Soheyl Sabet; Bedriye Koyuncu Sokmen; Nagihan Inan Gurcan; Yaman Tokat; Cavlan Ciftci

    doi:10.21203/rs.3.rs-28858/v1 Date: 2020-05-14 Source: ResearchSquare

    Background/Aim: Severe acute respiratory syndrome MESHD coronavirus 2 (SARS CoV-2) has deeply affected life all over the World. The World Health Organization named this disease MESHD as COVID-19. The most important factor in the transmission TRANS of the disease is asymptomatic MESHD asymptomatic TRANS carriers TRANS. We’ve tested all oncology patients, that receive anti-cancer therapy, for COVİD-19 to prevent asymptomatic TRANS oncology patients from spreading infection MESHD and to make the decision to postpone chemotherapy in infected patients. Then, we analyzed the clinical and radiological findings of infected patients.Materials and Methods: Oncology patients who have indications of receiving anti-cancer treatment in the hospital were tested for COVID-19, two day prior to their treatment even if they were asymptomatic TRANS by collecting nasopharyngeal and oropharyngeal swab specimens for RT-PCR for viral RNA detection. Positive patients, underwent inspiratory phase of chest computed tomography (CT) examination. Infected patients were given the recommended treatment for COVID-19. Anti-cancer treatment of all patients that had positive PCR results was delayed for 14 days.Results: PCR test was positive in 28 of 312 patients that we tested, and the positivity rate was 8.9%. Three patients (10.7%) had symptoms; 2 of whom had dyspnea MESHD dyspnea HP and cough MESHD cough HP, and 1 had headache MESHD headache HP, and 25 patients (89.3%) had no symptoms.Conclusion: In oncology patients, who are receiving anti-cancer treatment, we have to recognize the asymptomatic TRANS COVID-19 infection MESHD. We recommend testing for COVID-19 in oncology patients receiving chemotherapy, periodically or before each anti-cancer treatment, in order to continue their treatment without any problems and to prevent the risk of transmission TRANS.

    Special Precautions in Oral and Maxillofacial Surgeries Regarding COVID-19 Transmission TRANS

    Authors: Matheus Francisco Barros Rodrigues; Layla Louise de Amorim Rocha; Rodrigo da Franca Acioly; Dennis Dinelly de Souza; Daniel do Carmo Carvalho; Rimsky Coelho Lopes da Rocha; Cristofe Coelho Lopes da Rocha

    id:10.20944/preprints202005.0135.v1 Date: 2020-05-07 Source: Preprints.org

    The World Health Organization has defined the outbreak of the new coronavirus as a public health emergency MESHD of international concern. The average age TRANS of patients affected by the disease MESHD caused by the virus ranges from 49 to 59 years. The symptoms of coronavirus disease MESHD 2019 (COVID-19) infection MESHD include fever MESHD fever HP, cough MESHD cough HP, acute respiratory disease MESHD, and, in severe cases, the disease MESHD may progress to pneumonia MESHD pneumonia HP and renal failure that may lead to death MESHD. Many oral and maxillofacial hospital procedures produce aerosol and droplets contaminated by blood SERO, bacteria, and viruses. The purpose of this study is to gather recommendations from health authorities and scientific articles in order to educate surgeons regarding the procedures to assist and treat in oral and maxillofacial surgeries. The objective is to prevent the transmission TRANS of COVID-19 during the treatment of patients in urgent and emergency MESHD situations. The study’s methodology used the guidelines provided by the Brazilian College of Oral and Maxillofacial Surgery, in addition to the recommendations and epidemiologic data from national and international health authorities. The implementation of special precautions in oral and maxillofacial surgeries may elucidate questions related to the transmission TRANS of the disease by asymptomatic MESHD asymptomatic TRANS carriers TRANS and help control the spread of the virus.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.